INTS Stock Forecast 2025-2026
Distance to INTS Price Targets
INTS Price Momentum
10 Quality Stocks Worth Considering Now
Researching Intensity Therapeutics (INTS) after the drop? Our ex-Goldman Sachs analyst reveals if it made our list of 10 oversold quality stocks with strong growth potential.
Get our FREE market selloff report + exclusive analysis on INTS and similar high-potential opportunities.
Latest INTS Stock Price Targets & Analyst Predictions
Based on our analysis of 3 Wall Street analysts, INTS has a bullish consensus with a median price target of $8.50 (ranging from $4.00 to $15.00). Currently trading at $1.85, the median forecast implies a 359.5% upside. This outlook is supported by 5 Buy, 0 Hold, and 0 Sell ratings.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
INTS Analyst Ratings
INTS Price Target Range
Latest INTS Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for INTS.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Jan 13, 2025 | Alliance Global Partners | James Molloy | Buy | Initiates | $8.50 |
| Nov 21, 2024 | HC Wainwright & Co. | Swayampakula Ramakanth | Buy | Reiterates | $5.00 |
| Oct 31, 2024 | HC Wainwright & Co. | Swayampakula Ramakanth | Buy | Initiates | $5.00 |
| Jul 11, 2024 | Benchmark | Robert Wasserman | Speculative Buy | Reiterates | $12.00 |
| May 16, 2024 | Benchmark | Robert Wasserman | Speculative Buy | Reiterates | $12.00 |
| Mar 21, 2024 | Benchmark | Robert Wasserman | Speculative Buy | Reiterates | $12.00 |
| Nov 14, 2023 | Benchmark | Robert Wasserman | Speculative Buy | Reiterates | $12.00 |
| Aug 24, 2023 | Benchmark | Robert Wasserman | Speculative Buy | Reiterates | $12.00 |
| Jul 18, 2023 | Benchmark | Robert Wasserman | Speculative Buy | Initiates | $12.00 |
Intensity Therapeutics Inc. (INTS) Competitors
The following stocks are similar to Intensity Therapeutics based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Intensity Therapeutics Inc. (INTS) Financial Data
Intensity Therapeutics Inc. has a market capitalization of $28.08M with a P/E ratio of 0.0x. The company generates $0 in trailing twelve-month revenue with a 0.0% profit margin.
Revenue growth is N/A quarter-over-quarter, while maintaining an operating margin of 0.0% and return on equity of -202.3%.
Valuation Metrics
Growth & Margins
Financial Health
Get All 10 Quality Stocks For This Market Selloff
Still researching investments after the market drop? Our ex-Goldman Sachs analyst has already identified the 10 highest-quality oversold stocks with strong fundamentals and upside potential.
Why spend hours researching when we've already done the work? Get instant access to our complete market selloff analysis.
Intensity Therapeutics Inc. (INTS) Business Model
About Intensity Therapeutics Inc.
Develops innovative cancer treatments using immunotherapy.
Intensity Therapeutics Inc. focuses on creating proprietary immune-based drug products that integrate chemotherapy with immunotherapy. The company primarily generates revenue through the development and commercialization of its novel cancer therapies, particularly targeting solid tumors.
The company employs its DfuseRxSM technology platform to enhance treatment efficacy and reduce side effects for various cancers, including breast, colorectal, and liver cancers. With ongoing clinical trials, Intensity Therapeutics is positioned as a key player in advancing biotech research and improving patient outcomes in oncology.
Company Information
Sector
Healthcare
Industry
Biotechnology
Employees
5
CEO
Mr. Lewis H. Bender M.A., M.B.A., M.S.
Country
United States
IPO Year
2022
Website
www.intensitytherapeutics.comIntensity Therapeutics Inc. (INTS) Latest News & Analysis
Intensity Therapeutics Reports 2024 Year End Financial Results and Provides Corporate Update
1 month agoIntensity Therapeutics has 32 sites contracted for the INVINCIBLE-3 Study and 8 Swiss sites for INVINCIBLE-4. Recent data presentations occurred at oncology conferences in late 2024.
Updates on clinical studies and financial results from Intensity Therapeutics signal progress in cancer therapies, potentially impacting stock performance and investor confidence in the biotech sector.
Intensity Therapeutics' INVINCIBLE-3 Study on sarcoma therapies continues recruitment in multiple countries. The Data Monitoring Committee approved ongoing Phase 3 trials without modifications.
The continuation of the INVINCIBLE-3 study without modifications signals strong data integrity, potentially boosting investor confidence in Intensity Therapeutics' pipeline and future growth.
Intensity Therapeutics Provides Business Update Highlighting Key Achievements with Lead Drug Candidate INT230-6
3 months agoIntensity Therapeutics received regulatory approval for its Phase 3 study of INT230-6 in metastatic soft tissue sarcoma and activated sites for a Phase 2 study in early-stage TNBC.
Approval of Phase 3 and Phase 2 studies for INT230-6 signals progress in cancer therapy development, potentially impacting Intensity Therapeutics' stock value and market position positively.
Intensity Therapeutics is conducting ongoing enrollment at seven sites in Switzerland for its immune-based cancer therapies, collaborating with SAKK, a prominent clinical research institute.
The activation of trial sites in Switzerland for Intensity Therapeutics' novel cancer therapies signals progress in their clinical development, potentially influencing stock performance and investor sentiment.
Intensity Therapeutics, Inc. has secured a securities purchase agreement to sell 1,237,113 shares of common stock at $2.425 each to a healthcare-focused institutional investor.
Intensity Therapeutics' direct offering indicates investor confidence and raises capital for further development of its cancer therapies, which could impact stock valuation and future growth potential.
Intensity Therapeutics reported Phase 1/2 data showing a median overall survival of 21.3 months for INT230-6, significantly higher than the synthetic control of 6.7 months. The INVINCIBLE-3 Study is recruiting 333 patients globally.
Positive Phase 1/2 data indicates significant survival benefits for a new cancer therapy, attracting interest in Intensity Therapeutics and potentially impacting stock performance.
Frequently Asked Questions About INTS Stock
What is Intensity Therapeutics Inc.'s (INTS) stock forecast for 2025?
Based on our analysis of 3 Wall Street analysts, Intensity Therapeutics Inc. (INTS) has a median price target of $8.50. The highest price target is $15.00 and the lowest is $4.00.
Is INTS stock a good investment in 2025?
According to current analyst ratings, INTS has 5 Buy ratings, 0 Hold ratings, and 0 Sell ratings. The stock is currently trading at $1.85. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for INTS stock?
Wall Street analysts predict INTS stock could reach $8.50 in the next 12 months. This represents a 359.5% increase from the current price of $1.85. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Intensity Therapeutics Inc.'s business model?
Intensity Therapeutics Inc. focuses on creating proprietary immune-based drug products that integrate chemotherapy with immunotherapy. The company primarily generates revenue through the development and commercialization of its novel cancer therapies, particularly targeting solid tumors.
What is the highest forecasted price for INTS Intensity Therapeutics Inc.?
The highest price target for INTS is $15.00 from at , which represents a 710.8% increase from the current price of $1.85.
What is the lowest forecasted price for INTS Intensity Therapeutics Inc.?
The lowest price target for INTS is $4.00 from at , which represents a 116.2% increase from the current price of $1.85.
What is the overall INTS consensus from analysts for Intensity Therapeutics Inc.?
The overall analyst consensus for INTS is bullish. Out of 3 Wall Street analysts, 5 rate it as Buy, 0 as Hold, and 0 as Sell, with a median price target of $8.50.
How accurate are INTS stock price projections?
Stock price projections, including those for Intensity Therapeutics Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.